Teva Pharmaceutical Industries Ltd ADR Stock
We can see a decrease in the price for Teva Pharmaceutical Industries Ltd ADR. Compared to yesterday it has lost -€0.400 (-1.550%).
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Teva Pharmaceutical Industries Ltd ADR.
With a target price of 27 € there is a slightly positive potential of 6.3% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 25.4 €.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | -1.550% | 3.673% | 13.901% | 57.764% | 18.140% | 208.252% | 198.122% |
| Bayer AG ADR | 1.700% | 4.678% | 30.657% | 90.426% | 80.444% | -31.154% | -23.504% |
| Roche Holding AG ADR | -1.300% | 2.864% | 9.153% | 25.461% | 27.949% | 10.827% | 19.456% |
| Astrazeneca ADR | -0.650% | -0.645% | 1.316% | 20.313% | 20.313% | 17.021% | 71.875% |
Comments
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Bank of America Corporation from $29.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $35.00 price target on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat